DOCSLIB.ORG

Novel Functional Strategy for Development of Highly Specific Antibody Drug Conjugates for Non-Hodgkin's Lymphoma

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Novel Functional Strategy for Development of Highly Specific Antibody Drug Conjugates for Non-Hodgkin's Lymphoma 10th Annual PEGS Europe 2018 Protein & Antibody Engineering Summit Abstracts Lisbon , Portugal 12 - 16 November 2018 ISBN: 978-1-5108-7883-9 Printed from e-media with permission by: Curran Associates, Inc. 57 Morehouse Lane Red Hook, NY 12571 Some format issues inherent in the e-media version may also appear in this print version. Copyright© (2018) by Cambridge EnerTech All rights reserved. Printed with permission by Curran Associates, Inc. (2020) For permission requests, please contact Cambridge EnerTech at the address below. Cambridge EnerTech Cambridge Innovation institute 250 First Avenue Suite 300 Needham, MA 02494 USA Phone: 781-972-5400 Fax: 781-972-5425 [email protected] Additional copies of this publication are available from: Curran Associates, Inc. 57 Morehouse Lane Red Hook, NY 12571 USA Phone: 845-758-0400 Fax: 845-758-2633 Email: [email protected] Web: www.proceedings.com TABLE OF CONTENTS NOVEL FUNCTIONAL STRATEGY FOR DEVELOPMENT OF HIGHLY SPECIFIC ANTIBODY DRUG CONJUGATES FOR NON-HODGKIN'S LYMPHOMA ................................................. 1 A. Andre, J. Dias, S. Aguiar, S. Oliveira, J. Ministro, L. Gano, J. Correia, L. Tavares, F. Aires-da-Silva MAX RANDOMISATION: DESIGNED, NON-DEGENERATE SATURATION MUTAGENESIS OF ARMADILLO REPEAT PROTEINS ............................................................................... 3 A. Chembath, M. Ashraf, B.P.G. Wagstaffe, Y. Stark, A. Pluckthun, A.V. Hine NOVEL MULTIMERS OF BICYCLIC PEPTIDES CLUSTER AND ACTIVATE CD137 (4- 1BB): A COSTIMULATORY T CELL CHECKPOINT RECEPTOR ................................................................ 4 L. Chen, J. Kristensson, G. Mudd, H. Harrison, R. Lani, K. McDonnell, P. Upadhyaya, F. An, J. Lahdenranta, P. Park, N. Keen, K. Hurov INFLUENCE OF CULTURE MEDIA COMPONENTS ON ANTIBODY GLYCOSYLATION PATTERN ............................................................................................................................................................ 5 D. Choi, W. Kang, J. Lee, G.H. Lee, J.H. Kim, W.S. Choi ABDURIN DRUG CONJUGATES: SMALL IN SIZE AND LONG HALF-LIFE TO IMPROVE LIFE TO IMPROVE ............................................................................................................................................ 6 J.W. Choi TARGETED DELIVERY OF ENDOSOMAL TOLL-LIKE RECEPTOR AGONISTS TO THE TUMOUR MICROENVIRONMENT FOR THE PROMOTION OF ANTI-TUMOUR IMMUNITY ......................................................................................................................................................... 7 D. Corogeanu, A. Beavil, S.N. Karagiannis, J.N. Arnold, S.S. Diebold DEVELOPMENT OF A CAPILLARY ISOELECTRIC FOCUSING (CIEF) METHOD FOR CHARGE ANALYSIS OF NOVEL BIOTHERAPEUTICS ............................................................................... 8 J. Cummins, N. Farrands, A. Splevins DEVELOPMENT OF A BLOOD-BRAIN BARRIER-PENETRATING ANTICALIN FOR NON- INVASIVE BRAIN DRUG DELIVERY ............................................................................................................. 9 F.C. Deuschle, A. Skerra A NOVEL ULTRA-HIGH THROUGHPUT SCREEN FOR MICROBIAL TRANSGLUTAMINASE .................................................................................................................................. 10 L. Deweid, H. Kolmar AUTOMATED ONE-TO-ONE LINKAGE OF PROTEINS AND PAYLOADS ............................................. 12 I. Dovgan, A. Hentz, O. Koniev, A. Ehkirch, S. Ursuegui, S. Delacroix, M. Riomet, F. Taran, S. Cianferani, S. Kolodych, A. Wagner ISOLATION OF CHICKEN-DERIVED ANTIBODY FRAGMENTS USING YEAST SURFACE DISPLAY ........................................................................................................................................................... 13 A. Elter, J. Grzeschik, S. Hinz, D. Yanakieva, S. Krah, T. Zollmann, G. Schwall, S. Zielonka, H. Kolmar MULTIFUNCTIONAL BIOLOGICS BASED ON IN VIVO MATURED 100% HUMAN VH DOMAINS ......................................................................................................................................................... 14 C. Enever, J. Legg, B. McGuinness, P. Bland-Ward, P. Pack CELL-BASED ASSAYS FOR SCREENING AND CHARACTERISATION OF ANTIBODY- DRUG CONJUGATES ...................................................................................................................................... 15 R. Forfar, S. Leonard, D. Moore, J. Large, C. Fernandes, R. Brown, C. Southern, D. Matthews, L. Friis, D. Taylor HIGH THROUGHPUT SELECTION OF HUMAN ANTIBODIES WITH ENHANCED DEVELOPABILITY PROPERTIES ................................................................................................................. 16 T. Gallagher, C. Sellick, V. Germaschewski, R. Williams, S. Suhr, D. Melvin THE USE OF IN VITRO ASSAYS TO REDUCE THE RISK OF UNWANTED IMMUNOGENICITY AND ACCELERATE CANCER IMMUNOTHERAPY DEVELOPMENT ................ 17 S. Giltaire, J. Lamy, T. Janss, T. Jonckheere, S. Pattijn ABGENESIS: AN INTEGRATED COMPUTATIONAL SOFTWARE EXPLORING NEW DEPTHS IN ANTIBODY AND IMMUNE REPERTOIRE SEQUENCE ANALYSIS ................................... 18 J. Glanville, D. Maurer, S. Youssef, S. Ives, C. Pettus, R. Newland, V. Chou, K. Hervold, C. Smith, G. Day, C. Jones, S. Daraeikia, A. Sanchez, J. Brysting DRUG CONJUGATES BASED ON ENGINEERED AFFIBODY MOLECULES ......................................... 19 T. Graslund, M. Altai, H. Liu, H. Ding, B. Mitran, P.H. Edqvist, V. Tolmachev, A. Orlova NOVEL CELL CULTURE SYSTEM FOR LONG TERM STABLE IGG AND PROTEIN PRODUCTION .................................................................................................................................................. 20 M. Hagihara, S. Ohya, T. Harada, S. Yamada IMPLEMENTATION OF GENETIC CIRCUITS IN THE YEAST SACCHAROMYCES CEREVISIAE FOR TIGHTLY REGULATED GENE EXPRESSION ............................................................ 22 D. Happel, A. Hofmann, A. Christmann, H. Kolmar RAPID ONLINE AND INPROCESS CHARACTERIZATION OF CETUXIMAB FD- GLYCOPROFILE BY DIRECT MONITORING AND CONTROL ................................................................ 23 M. Hedstrom, S. Bjork, D. Erlandsson, M. Westesson, B. Mattiasson PREDICTING PROTEIN-PROTEIN BINDING SITES AND EPITOPE MAPPING ...................................... 25 A. Henry, N. Thorsteinson, A. Ajamian, J. Gunn, P. Labute DEVELOPMENT AND EVALUATION OF T-ZAP2, A NOVEL ANTIBODY-DRUG CONJUGATE FOR THE TREATMENT OF HER2 POSITIVE BREAST CANCER ..................................... 26 R.M. Hoffmann, S. Crescioli, D. Thurston, S. Karagiannis PASYLATED COLCHICALIN - A POSSIBLE ANTIDOTE FOR ACUTE COLCHICINE INTOXICATION WITH OPTIMIZED PHARMACOKINETICS .................................................................... 27 E. Ilyukhina, M. Barkovskiy, M. Dauner, A. Eichinger, J. Stenzel, N. Jung, H. Neuberger, F. Eyer, A. Skerra SELECTION OF SCAFFOLD PROTEINS FOR ANTIBODY MIMETICS .................................................... 28 T. Ito, H. Nishi, T. Kameda, T. Niide, H. Nakazawa, M. Umetsu APPRAISAL OF LEUCINE-RICH ALPHA-2-GLYCOPROTEIN 1 (LRG1) AS A TARGET FOR A POTENTIAL ANTIBODY-DRUG CONJUGATE (ADC) ........................................................................... 29 F. Javaid, S.E. Moss, J. Greenwood, V. Chudasama ANTIBODY-MEDIATED INHIBITION OF PEPTIDYL ARGININE DEIMINASE (PPAD) FROM PORPHYROMONAS GINGIVALIS .................................................................................................... 30 J.Z. Kaczmarek, J.Z. Kaczmarek, D.N. Larsen, B. Szmigielski, J. Potempa, P.D. Skottrup, P. Hojrup DRUG-TARGET-COMPLEX SPECIFIC ANTIBODIES FOR PHARMACOKINETIC ANALYSIS OF BIOTHERAPEUTICS ............................................................................................................. 32 S.J. Kellmann, C. Frisch, S. Harth, A. Knappik APPLICATIONS FOR HYPERIMMUNE, AUTOIMMUNE DIVERSIMAB™ MICE IN ANTIBODY DISCOVERY ............................................................................................................................... 33 R.P. Kelly, B. Bouchard, R. Abdullah, R. Sahoo, R. Subburathinam, A. Bemis, K. Teague, E. Batitay, H. Wagner, J. Gabriel, C. Souders, T. Mullen, G. Hilow, D. Turner OBTAINING OF A PROTEIN WITH MOLECULAR RECOGNITION BY GRAFTING A FUNCTIONAL PEPTIDE SEQUENCE WITH THE SAME SECONDARY STRUCTURE .......................... 34 M. Kikuchi, T. Niide, H. Nakazawa, H. Imanaka, M. Umetsu INTEGRATED EARLY STAGE DEVELOPMENT STRATEGY AS RISK MANAGEMENT TOOL FOR GLOBAL DEVELOPMENT ......................................................................................................... 35 N. Kinsella, J.B. Holz NATURAL AND FULLY HUMAN ANTIBODIES FOR DIAGNOSTICS AND THERAPY ........................ 36 J. Kugler MINIATURIZATION AND OPTIMIZATION OF A TWO-PLASMID EXPRESSION PATHWAY IN MYTXTL® CELL-FREE PROTEIN EXPRESSION KIT (ARBOR BIOSCIENCES) USING LABCYTE ECHO® ACOUSTIC TECHNOLOGY ................................................. 37 A. Lehto, E. Eggenstein, J. Bailey, J.M. Rouillard, J. Lesnick HOS BIOSIMILARITY AND COMPARABILITY: OBJECTIVE, QUANTIFIABLE HOS COMPARISONS - A BIOSIMILAR CASE STUDY UTILIZING CIRCULAR DICHROISM ....................... 38 T. Lester, M. Textor DESIGNING AN ARTIFICIAL GOLGI REACTOR FOR CELL-FREE GLYCOSYLATION ...................... 39 E. Makrydaki, I.M. Ramirez, L. Bouche, S. Haslam, C. Kontoravdi, K.M. Polizzi BINDERS FOR CHALLENGING TASKS - A HIGH-THROUGHPUT DARPIN SELECTION PIPELINE ..........................................................................................................................................................
Load more

Recommended publications
  • Protein Conjugation with Triazolinediones: Switching from a General Tyrosine-Selective Labeling Method to a Highly Specific Tryptophan Bioconjugation Strategy Klaas W
    Protein Conjugation with Triazolinediones: Switching from a General Tyrosine-Selective Labeling Method to a Highly Specific Tryptophan Bioconjugation Strategy Klaas W. Decoene,† Kamil Unal,‡ An Staes⟠Ψ, Kris Gevaert⟠, Johan M. Winne,‡ Annemieke Madder†* † Organic and Biomimetic Chemistry Research group OBCR, Department of Organic and Macromolecular Chemistry, Faculty of Sciences, Ghent University, Krijgslaan 281 S4, 9000 Ghent, Belgium ‡ Organic Synthesis group, Department of Organic and Macromolecular Chemistry, Faculty of Sciences, Ghent University, Krijgslaan 281 S4, 9000 Ghent, Belgium ⟠ VIB Centre for Medical Biotechnology, Technologiepark-Zwijnaarde 75, 9052 Ghent, Belgium & Department of Bio- molecular Medicine, Ghent University, Technologiepark-Zwijnaarde 75, 9052 Ghent, Belgium Ψ VIB core facility , VIB Centre for Medical Biotechnology, Technologiepark-Zwijnaarde 75, 9052 Ghent, Belgium ABSTRACT: Selective labeling of tyrosine residues in peptides and proteins can be achieved via a 'tyrosine-click' reaction with triazolinedione reagents (TAD). We have found that tryptophan residues are in fact often also labeled with this reagent. This off-target labeling is only observed at very low levels in protein bioconjugation but remains under the radar due to the low relative abundance of tryptophan compared to tyrosines in natural proteins, and because of the low availability and ac- cessibility of their nucleophilic positions at the solvent-exposed protein surface. Moreover, because TAD-Trp adducts are known to be readily thermoreversible, it can be challenging to detect these physiologically stable but thermally labile modi- fications using several MS/MS techniques. We have found that fully solvent-exposed tryptophan side chains are kinetically favored over tyrosines under almost all conditions, and this selectivity can even be further enhanced by modifying the pH of the aqueous buffer to effect selective Trp-labeling.
    [Show full text]
  • Strategies and Challenges for the Next Generation of Therapeutic Antibodies
    FOCUS ON THERAPEUTIC ANTIBODIES PERSPECTIVES ‘validated targets’, either because prior anti- TIMELINE bodies have clearly shown proof of activity in humans (first-generation approved anti- Strategies and challenges for the bodies on the market for clinically validated targets) or because a vast literature exists next generation of therapeutic on the importance of these targets for the disease mechanism in both in vitro and in vivo pharmacological models (experi- antibodies mental validation; although this does not necessarily equate to clinical validation). Alain Beck, Thierry Wurch, Christian Bailly and Nathalie Corvaia Basically, the strategy consists of develop- ing new generations of antibodies specific Abstract | Antibodies and related products are the fastest growing class of for the same antigens but targeting other therapeutic agents. By analysing the regulatory approvals of IgG-based epitopes and/or triggering different mecha- biotherapeutic agents in the past 10 years, we can gain insights into the successful nisms of action (second- or third-generation strategies used by pharmaceutical companies so far to bring innovative drugs to antibodies, as discussed below) or even the market. Many challenges will have to be faced in the next decade to bring specific for the same epitopes but with only one improved property (‘me better’ antibod- more efficient and affordable antibody-based drugs to the clinic. Here, we ies). This validated approach has a high discuss strategies to select the best therapeutic antigen targets, to optimize the probability of success, but there are many structure of IgG antibodies and to design related or new structures with groups working on this class of target pro- additional functions.
    [Show full text]
  • International Patent Classification: KR, KW, KZ, LA, LC, LK, LR, LS, LU
    ( 2 (51) International Patent Classification: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, A61K 39/42 (2006.01) C07K 16/10 (2006.01) HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, C07K 16/08 (2006.01) KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (21) International Application Number: OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, PCT/US20 19/033 995 SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (22) International Filing Date: TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. 24 May 2019 (24.05.2019) (84) Designated States (unless otherwise indicated, for every (25) Filing Language: English kind of regional protection available) . ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, (26) Publication Language: English UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (30) Priority Data: TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, 62/676,045 24 May 2018 (24.05.2018) US EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (71) Applicant: LANKENAU INSTITUTE FOR MEDICAL TR), OAPI (BF, BJ, CF, CG, Cl, CM, GA, GN, GQ, GW, RESEARCH [US/US]; 100 Lancaster Avenue, Wyn- KM, ML, MR, NE, SN, TD, TG).
    [Show full text]
  • 2010.01) C07k 14/74 (2006.01
    ( (51) International Patent Classification: su 215 123 (CN). LIN, Yanni; F2, Building B20, Sangt- C07K 19/00 (2006.0 1) C12N 5/0783 (20 10.01) ian Street 218, Suzhou Industrial Park, Suzhou, Jiangsu C07K 14/74 (2006.01) A61K 35/1 7 (2015.01) 215123 (CN). ZHENG, Xiaocui; F2, Building B20, Sangt- C12N 15/62 (2006.01) A61P 35/00 (2006.01) ian Street 218, Suzhou Industrial Park, Suzhou, Jiangsu 215123 (CN). KONG, Hongmei; F2, Building B20, Sangt- (21) International Application Number: ian Street 218, Suzhou Industrial Park, Suzhou, Jiangsu PCT/ CN2020/ 1081 16 215123 (CN). WANG, Wenbo; F2, Building B20, Sangtian (22) International Filing Date: Street 218, Suzhou Industrial Park, Suzhou, Jiangsu 215 123 10 August 2020 (10.08.2020) (CN). FENG, Aihua; F2, Building B20, Sangtian Street 218, Suzhou Industrial Park, Suzhou, Jiangsu 215 123 (CN). (25) Filing Language: English (74) Agent: J. Z. M. C. PATENT AND TRADEMARK LAW (26) Publication Language: English OFFICE (GENERAL PARTNERSHIP); YU, Mingwei, (30) Priority Data: Room 5022, No. 335, Guo Ding Road, Yang Pu District, 201910746355.8 13 August 2019 (13.08.2019) CN Shanghai 200433 (CN). PCT/ CN20 19/124321 (81) Designated States (unless otherwise indicated, for every 10 December 2019 (10. 12.2019) CN kind of national protection av ailable) . AE, AG, AL, AM, (71) Applicant: CURE GENETICS CO., LTD. [CN/CN]; AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, Biobay A4-5 10, Xinghu Street 218, Suzhou Industrial Park, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, Suzhou, Jiangsu 215 123 (CN).
    [Show full text]
  • EURL ECVAM Recommendation on Non-Animal-Derived Antibodies
    EURL ECVAM Recommendation on Non-Animal-Derived Antibodies EUR 30185 EN Joint Research Centre This publication is a Science for Policy report by the Joint Research Centre (JRC), the European Commission’s science and knowledge service. It aims to provide evidence-based scientific support to the European policymaking process. The scientific output expressed does not imply a policy position of the European Commission. Neither the European Commission nor any person acting on behalf of the Commission is responsible for the use that might be made of this publication. For information on the methodology and quality underlying the data used in this publication for which the source is neither Eurostat nor other Commission services, users should contact the referenced source. EURL ECVAM Recommendations The aim of a EURL ECVAM Recommendation is to provide the views of the EU Reference Laboratory for alternatives to animal testing (EURL ECVAM) on the scientific validity of alternative test methods, to advise on possible applications and implications, and to suggest follow-up activities to promote alternative methods and address knowledge gaps. During the development of its Recommendation, EURL ECVAM typically mandates the EURL ECVAM Scientific Advisory Committee (ESAC) to carry out an independent scientific peer review which is communicated as an ESAC Opinion and Working Group report. In addition, EURL ECVAM consults with other Commission services, EURL ECVAM’s advisory body for Preliminary Assessment of Regulatory Relevance (PARERE), the EURL ECVAM Stakeholder Forum (ESTAF) and with partner organisations of the International Collaboration on Alternative Test Methods (ICATM). Contact information European Commission, Joint Research Centre (JRC), Chemical Safety and Alternative Methods Unit (F3) Address: via E.
    [Show full text]
  • Generation of Novel Intracellular Binding Reagents Based on the Human Γb-Crystallin Scaffold
    Generation of novel intracellular binding reagents based on the human γB-crystallin scaffold Dissertation zur Erlangung des akademischen Grades doctor rerum naturalium (Dr. rer. nat.) vorgelegt der Naturwissenschaftlichen Fakultät I-Biowissenschaften der Martin-Luther-Universität Halle-Wittenberg Institut für Biochemie und Biotechnologie von Ewa Mirecka geboren am 17. Dezember 1976 in Gdynia, Polen Table of contents Table of contents 1. INTRODUCTION.........................................................................................................1 1.1 Monoclonal antibodies as a biomolecular scaffold..........................................................1 1.2 Binding molecules derived from non-immunoglobulin scaffolds.....................................3 1.2.1 Alternative protein scaffolds – general considerations............................................................ 3 1.2.2 Application of alternative binding molecules ........................................................................... 6 1.3 Affilin – novel binding molecules based on the human γB-crystallin scaffold................... 6 1.3.1 Human γB-crystallin as a molecular scaffold........................................................................... 6 1.3.2 Generation of a human γB-crystallin library and selection of first-generation Affilin molecules ................................................................................................................................ 8 1.4 Selection of binding proteins by phage display ...................................................................
    [Show full text]
  • Monobodies and Other Synthetic Binding Proteins for Expanding Protein Science
    Reviews Protein Science DOI 10.1002/pro.3148 Monobodies and Other Synthetic Binding Proteins for Expanding Protein Science Fern Sha,1,4 Gabriel Salzman,1 Ankit Gupta1,2 and Shohei Koide1,2,3* 1Department of Biochemistry and Molecular Biology, The University of Chicago, Chicago, IL 60637, USA 2Perlmutter Cancer Center, New York University Langone Medical Center, New York, NY 10016, USA 3Department of Biochemistry and Molecular Pharmacology New York University School of Medicine, New York, NY 10016, USA 4Present address, Janelia Research Campus, Howard Hughes Medical Institute, Ashburn, VA 20148, USA *Correspondence to: Shohei Koide, Perlmutter Cancer Center, New York University Langone Medical Center, New York, NY 10016, USA. E-mail: [email protected] Abstract Synthetic binding proteins are constructed using non-antibody molecular scaffolds. Over the last two decades, in-depth structural and functional analyses of synthetic binding proteins have improved combinatorial library designs and selection strategies, which have resulted in potent platforms that consistently generate binding proteins to diverse targets with affinity and specificity that rival those of antibodies. Favorable attributes of synthetic binding proteins, such as small size, freedom from disulfide bond formation and ease of making fusion proteins, have enabled their unique applications in protein science, cell biology and beyond. Here, we review recent studies that illustrate how synthetic binding proteins are powerful probes that can directly link structure and function,
    [Show full text]
  • Anticalins Versus Antibodies: Made-To-Order Binding Proteins for Small Molecules Gregory a Weiss * and Henry B Lowman
    Minireview R177 Anticalins versus antibodies: made-to-order binding proteins for small molecules Gregory A Weiss * and Henry B Lowman Engineering proteins to bind small molecules presents a challenge as daunting as Department of Protein Engineering, Genentech, Inc., drug discovery, for both hinge upon our understanding of receptor^ligand 1 DNA Way, South San Francisco, CA 94080, USA molecular recognition. However, powerful techniques from combinatorial *Present address: Department of Chemistry, molecular biology can be used to rapidly select arti¢cial receptors. While University of California, Irvine, CA 92697, USA traditionally researchers have relied upon antibody technologies as a source of new binding proteins, the lipocalin scaffold has recently emerged as an adaptable Correspondence: HB Lowman receptor for small molecule binding. `Anticalins', engineered lipocalin variants, E-mail: [email protected] offer some advantages over traditional antibody technology and illuminate Keywords: Antibody; Anticalin; Small molecule features of molecular recognition between receptors and small molecule ligands. ligand Received: 19 June 2000 Accepted: 10 July 2000 Published: 1 August 2000 Chemistry & Biology 2000, 7:R177^R184 1074-5521 / 00 / $ ^ see front matter ß 2000 Published by Elsevier Science Ltd. PII: S 1 0 7 4 - 5 5 2 1 ( 0 0 ) 0 0 0 1 6 - 8 Introduction of randomly mutated proteins displayed on the surface of The challenge of discovering small molecule ligands for ¢lamentous bacteriophage, viruses capable of infecting protein receptors is well appreciated by, among others, only bacteria (reviewed in [4]). Diversity can be targeted the pharmaceutical industry, which spent the majority of to particular regions of a displayed protein through stan- its $24 billion pharmaceutical research and development dard molecular biology techniques [5], or can be distrib- budget in 1999 on small molecule drug discovery [1].
    [Show full text]
  • WO 2017/013231 Al 26 January 2017 (26.01.2017) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization I International Bureau (10) International Publication Number (43) International Publication Date WO 2017/013231 Al 26 January 2017 (26.01.2017) P O P C T (51) International Patent Classification: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, C07K 14/705 (2006.01) C07K 16/00 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (21) International Application Number: KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, PCT/EP20 16/067468 MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (22) International Filing Date: PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, 2 1 July 20 16 (21 .07.2016) SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, 62/194,882 2 1 July 2015 (21.07.2015) TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, 62/364,414 20 July 2016 (20.07.2016) TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, (72) Inventors; and LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, (71) Applicants : XIANG, Sue D.
    [Show full text]
  • Bispecific Immunomodulatory Antibodies for Cancer Immunotherapy
    Published OnlineFirst June 9, 2021; DOI: 10.1158/1078-0432.CCR-20-3770 CLINICAL CANCER RESEARCH | REVIEW Bispecific Immunomodulatory Antibodies for Cancer Immunotherapy A C Belen Blanco1,2, Carmen Domínguez-Alonso1,2, and Luis Alvarez-Vallina1,2 ABSTRACT ◥ The recent advances in the field of immuno-oncology have here referred to as bispecific immunomodulatory antibodies, dramatically changed the therapeutic strategy against advanced have the potential to improve clinical efficacy and safety profile malignancies. Bispecific antibody-based immunotherapies have and are envisioned as a second wave of cancer immunotherapies. gained momentum in preclinical and clinical investigations Currently, there are more than 50 bispecific antibodies under following the regulatory approval of the T cell–redirecting clinical development for a range of indications, with promising antibody blinatumomab. In this review, we focus on emerging signs of therapeutic activity. We also discuss two approaches for and novel mechanisms of action of bispecific antibodies inter- in vivo secretion, direct gene delivery, and infusion of ex vivo acting with immune cells with at least one of their arms to gene-modified cells, which may become instrumental for the regulate the activity of the immune system by redirecting and/or clinical application of next-generation bispecific immunomod- reactivating effector cells toward tumor cells. These molecules, ulatory antibodies. Introduction of antibodies, such as linear gene fusions, domain-swapping strat- egies, and self-associating peptides and protein domains (Fig. 1B). The past decade has witnessed a number of cancer immunotherapy Multiple technology platforms are available for the design of bsAbs, breakthroughs, all of which involve the modulation of T cell–mediated allowing fine-tuning of binding valence, stoichiometry, size, flexi- immunity.
    [Show full text]
  • Anticalins: a Novel Class of Therapeutic Binding Proteins
    IPT 23 2007 30/8/07 08:54 Page 32 Biotechnology Anticalins: a Novel Class of Therapeutic Binding Proteins Anticalins – engineered human lipocalin proteins – provide a novel class of biopharmaceutical drug candidates with similar binding and recognition properties as antibodies, while offering several fundamental advantages. By Andreas M. Hohlbaum and Arne Skerra of Pieris AG Andreas M. Hohlbaum (Dr. rer. nat.) is Director of Science and Preclinical Development and member of the management of Pieris. He received his training in immunology and a PhD from the University of Konstanz, Germany, and pursued postdoctoral research at Boston University School of Medicine, US, in the areas of apoptosis, inflammation, innate immunity and tumour immunology. He obtained first-hand experience in commercially oriented Discovery Research during his time at the biopharmaceutical company, Dyax (Cambridge, Mass). Dr Hohlbaum joined Pieris as a Strategic Research Scientist, in February 2003 and was promoted to Assistant Director of Preclinical Research in February 2004. Since May 2006, he has directed Pieris’s research and development of proprietary and also partnered Anticalin-based biotherapeutics. Arne Skerra (Dipl.-Ing., Dr. rer. nat.) is Founder of Pieris, Member of its Supervisory Board, and Professor at the Technische Universität München, where he heads the Institute of Biological Chemistry. He holds a Diploma degree in Chemistry from the Technische Universität Darmstadt, and a PhD in Biochemistry from the Ludwig-Maximilians-Universität München. After post- doctoral studies at the MRC Laboratory of Molecular Biology in Cambridge, UK, and a group leader position at the Max-Planck- Institute for Biophysics in Frankfurt am Main, he became Associate Professor for Protein Chemistry at the TU Darmstadt.
    [Show full text]
  • The Organizing Committee Gratefully Acknowledges the Symposium
    2nd Symposium on Higher Order Structure of Protein Therapeutics February 11 – 13, 2013 Hyatt Regency Baltimore on the Inner Harbor Baltimore, Maryland USA Organized by 1 Table of Contents Program Partners ..........................................................................................................3 Exhibitor and Media Partners.......................................................................................4 Acknowledgements ......................................................................................................5 Student Travel Grants ..................................................................................................6 Scientific Final Program Summary ..............................................................................7 Plenary and Session Abstracts .....................................................................................16 Technical Seminar I (Monday, February 11) Abstract ................................................55 Technical Seminar II (Tuesday, February 12) Abstract...............................................56 Technical Seminar III (Tuesday, February 12) Abstract .............................................57 Poster Abstracts ............................................................................................................58 2 The Organizing Committee gratefully acknowledges the Corporate Program Partners for their generous support of the 2nd Symposium on Higher Order Structure of Protein Therapeutics Sustaining Gold Program Partners AbbVie Inc.
    [Show full text]